Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE42.7600
- TODAY'S CHANGE (%)-0.1700 (-0.3960%)
- Bid / Lots42.7000/ 4
- Ask / Lots42.8200/ 4
- Open / Previous Close42.9300 / 42.9300
- Day Range
- 52 Week Range
- Volume58,311
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 804 | 42.715 |
| 09:38 ET | 1567 | 42.53 |
| 09:39 ET | 100 | 42.425 |
| 09:45 ET | 100 | 42.24 |
| 09:52 ET | 1238 | 42.37 |
| 09:54 ET | 300 | 42.4 |
| 10:08 ET | 1300 | 42.525 |
| 10:14 ET | 1314 | 42.76 |
| 10:15 ET | 1700 | 42.72 |
| 10:17 ET | 200 | 42.6425 |
| 10:19 ET | 400 | 42.575 |
| 10:24 ET | 704 | 42.52 |
| 10:28 ET | 300 | 42.555 |
| 10:30 ET | 1400 | 42.58 |
| 10:32 ET | 100 | 42.57 |
| 10:33 ET | 100 | 42.575 |
| 10:35 ET | 300 | 42.51 |
| 10:37 ET | 206 | 42.55 |
| 10:42 ET | 900 | 42.575 |
| 10:46 ET | 302 | 42.64 |
| 10:48 ET | 100 | 42.58 |
| 10:53 ET | 100 | 42.57 |
| 10:55 ET | 100 | 42.57 |
| 10:57 ET | 1552 | 42.77 |
| 11:04 ET | 500 | 42.82 |
| 11:06 ET | 755 | 42.885 |
| 11:08 ET | 200 | 42.855 |
| 11:09 ET | 400 | 42.87 |
| 11:20 ET | 200 | 42.85 |
| 11:26 ET | 500 | 42.855 |
| 11:27 ET | 1200 | 42.92 |
| 11:29 ET | 379 | 42.9 |
| 11:31 ET | 800 | 42.805 |
| 11:33 ET | 300 | 42.74 |
| 11:36 ET | 990 | 42.83 |
| 11:38 ET | 100 | 42.9 |
| 11:40 ET | 100 | 42.815 |
| 11:42 ET | 600 | 42.8 |
| 11:44 ET | 500 | 42.895 |
| 11:54 ET | 920 | 42.975 |
| 12:00 ET | 1000 | 42.905 |
| 12:02 ET | 100 | 42.885 |
| 12:09 ET | 300 | 42.88 |
| 12:14 ET | 100 | 42.87 |
| 12:16 ET | 1100 | 42.885 |
| 12:18 ET | 732 | 42.93 |
| 12:21 ET | 800 | 42.84 |
| 12:27 ET | 1000 | 42.735 |
| 12:30 ET | 300 | 42.63 |
| 12:34 ET | 100 | 42.57 |
| 12:36 ET | 200 | 42.52 |
| 12:38 ET | 100 | 42.5 |
| 12:43 ET | 100 | 42.54 |
| 12:48 ET | 200 | 42.52 |
| 12:52 ET | 1911 | 42.64 |
| 12:54 ET | 400 | 42.645 |
| 12:57 ET | 1718 | 42.85 |
| 12:59 ET | 200 | 42.84 |
| 01:01 ET | 400 | 42.82 |
| 01:03 ET | 200 | 42.82 |
| 01:06 ET | 1200 | 42.715 |
| 01:08 ET | 600 | 42.79 |
| 01:10 ET | 300 | 42.76 |
Yesterday
May 7, 2024
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference, from 4:01PM ET on Tuesday May 07, 2024 by Dow Jones
4:01PM ET on Tuesday May 07, 2024 by Dow Jones
May 2, 2024
Apr 16, 2024
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting, from 8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 12, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham, from 7:13AM ET on Friday Apr 12, 2024 by Dow Jones
7:13AM ET on Friday Apr 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 3.2B | -15.7x | --- |
SpringWorks Therapeutics Inc | 3.1B | -8.5x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Summit Therapeutics Inc | 3.5B | -3.1x | --- |
IDEAYA Biosciences Inc | 3.1B | -20.6x | --- |
Apogee Therapeutics Inc | 2.9B | -30.1x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.73 |
Book Value | $12.31 |
P/E Ratio | -15.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
